Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 1

Status

Terminated 2Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 9INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6Thoracic 1Head & Neck 1

Conditions

Melanoma 6Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Patient Preference 1Neoplasms 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × Opdualag × Clear all
NCT05625399 2026-06-03

RELATIVITY-127

Bristol-Myers Squibb

Phase 3 Active not recruiting
579 enrolled
Dermatologic

Melanoma

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06246916 2026-05-06

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Regeneron Pharmaceuticals

Phase 3 Recruiting
560 enrolled
Dermatologic

Melanoma

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Bristol-Myers Squibb

Phase 2 Active not recruiting
100 enrolled 11 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Patient Preference

NCT05002569 2026-01-08

RELATIVITY-098

Bristol-Myers Squibb

Phase 3 Terminated
1,093 enrolled 15 charts
Dermatologic

Melanoma

NCT05970497 2025-05-18

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Krystal Biotech, Inc.

Phase 1/2 Recruiting
240 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡